Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat(Cornell University), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Parisa Momtaz(Cornell University), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Kaitlin M. Woo(Cornell University), Thu-Oanh Dang(Cornell University), Richard D. Carvajal(Northwell Health), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Katherine S. Panageas(Mayo Clinic), Nelly G. Adel(Cornell University), Margaret K. Callahan(Cornell University)
Cited by 1,071
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k